Scientific Leadership & International Recognition
In 2025, the FORMaT team presented at multiple major international conferences, including:
• The American Thoracic Society (ATS) Conference 2025
• The 48th European Cystic Fibrosis Society Conference
• The 8th World Bronchiectasis Conference
• The European Respiratory Society Congress 2025
• The North American Cystic Fibrosis Conference 2025
• The Australian Non-tuberculous Mycobcaterium Symposium 2025
These presentations showcased new insights into Mycobacterium abscessus lung disease treatment toxicity, immune biomarkers, and novel medical imaging markers—highlighting FORMaT’s growing reputation as the leading global platform for Mycobacterium abscessus lung disease research.
Below: FORMaT Senior Research Pharmacists Mr Daniel Hicks and Mrs Megan Rice presenting “Adverse Events leading to treatment withdrawal and interruption in Mycobacteroides abscessus complex pulmonary disease” abstract at the 8th World Bronchiectasis Conference in Brisbane, Australia.
Below: “Adverse Events leading to treatment withdrawal and interruption in Mycobacteroides abscessus complex pulmonary disease” abstract presentation at 8th World Bronchiectasis Conference in Brisbane, Australia.
Below: Ms Kara Brady presenting “An Overview of the FORMaT Trial” at the NTM Symposium Australia 2025 in Brisbane, Australia.
Professor Rachel Thomson presenting “A comparison of FORMaT Observation versus Intervention participants at Baseline” at the NTM Symposium Australia 2025 in Brisbane, Australia.
Mr Daniel Hicks presenting “Safety, Tolerance and Pharmacovigilance in the FORMaT Trial” at the NTM Symposium Australia 2025 in Brisbane, Australia.
FORMaT team panel discussion at the NTM Symposium Australia 2025 in Brisbane, Australia.
